Eribulin Mesylate in Treating Patients With Recurrent Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer

Inclusion Criteria

• •Histologically or cytologically confirmed ovarian epithelial, primary peritoneal cavity, or fallopian tube cancer
• •* Recurrent disease after ≥ 1 prior therapy, meeting 1 of the following criteria:
• •* Platinum-resistant disease (progression-free interval \< 6 months)
• •* Platinum-sensitive disease (progression-free interval ≥ 6 months)
• •Measurable disease, defined as ≥ 1 unidimensionally measurable lesion ≥ 20 mmby conventional techniques OR ≥ 10 mm by spiral CT scan
• •No known brain metastasis
• •Life expectancy \> 2 months
• •ECOG performance status (PS) 0-1 OR Karnofsky PS 70-100%
• •Absolute neutrophil count ≥ 1,500/mm³
• •Platelet count ≥ 100,000/mm³
• •WBC ≥ 3,000/mm\^3
• •Bilirubin normal
• •AST and ALT ≤ 2.5 times upper limit of normal
• •Creatine normal OR creatinine clearance ≥ 60 mL/min
• •Not pregnant or nursing
• •Negative pregnancy test
• •Fertile patients must use effective contraception
• •No prior invasive malignancy within the past 5 years except nonmelanoma skin cancer
• •* Stage IA or IB endometrial cancer within the past 5 years allowed provided patient is considered disease free
• •No history of allergic reaction attributed to compounds of similar chemical or biological composition to E7389
• •No HIV positivity
• •No ongoing or active infection
• •No cardiac arrhythmia
• •No unstable angina pectoris
• •No symptomatic congestive heart failure
• •No psychiatric illness or social situations that would preclude study compliance
• •No other uncontrolled intercurrent illness
• •See Disease Characteristics
• •Recovered from effects of recent surgery, radiotherapy, or chemotherapy
• •No more than 2 prior cytotoxic therapies with no more than 1 non platinum, non taxane regimen
• •No prior E7389
• •More than 14 days since prior hormonal therapy
• •More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C)
• •More than 4 weeks since prior radiotherapy
• •No concurrent antitumor hormonal therapy
• •No other concurrent investigational agents
• •No other concurrent anticancer agents or therapies
• •No granulocyte colony-stimulating factors during the first course of study therapy